I. COMMENCED TRADING IN JULY

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)@

Lead, Other Underwriters

Gross (US$M)

Post-Offering Market Cap (M)%


INITIAL OFFERINGS

 

There were no initial public offerings that commenced in July.

 

Total: $0M
Number of IPOs in July: 0
Average value of July IPOs: $0M
Number of IPOs in 2010: 10
Total raised in IPOs in 2010: $611.06M
Average value of IPOs in 2010: $61.11M

 

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)@

Lead, Other Underwriters

Gross (US$M)

Post-Offering Market Cap (M)%


FOLLOW-ON OFFERINGS

 

BioMimetic Therapeutics Inc. (BMTI)1

7/14

7/15

5.64S

$8.50

27.74

J.P. Morgan Securities
Canaccord Genuity

$47.94

$235.79

 

Total: $47.94M
Number of follow-on offerings in July: 1
Average value of July follow-ons: $47.94M
Number of follow-on offerings in 2010: 41
Total raised in follow-ons in 2010: $2,119.87M
Average value of follow-ons in 2010: $51.7M


Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.
% Market capitalization is calculated based on the offering price.
Currency conversions are based on exchange rates at the time of the deal.
1 Includes BioMimetics' overallotment option: 642,000 shares.

 

II. FILED AND PENDING

 

Company (Symbol)#

Date Filed

Shares/Units (M)

Price

Shares Out

Lead, Other Underwriters (M)@

Gross (US$M)


INITIAL OFFERINGS

 

Aldagen Inc. (ALDH)

10/29/09

Units

N/A

N/A

Boenning & Scattergood
Ladenburg Thalmann (co-lead)
National Securities Corp.

$46

 

BG Medicine Inc. (BGMD)

1/29/10

N/A

N/A

N/A

Jefferies & Co.
UBS Investment Bank (co-lead)
Cowen & Co.
Thomas Weisel Partners

$86.25

 

Human Stem Cell Institute (Russia)1

10/7/09

15S

RUB 9-11
(30-37 cents)

N/A

N/A

$5.025

 

Ikaria Inc. (IKAR)

5/13/10

N/A

N/A

N/A

Goldman Sachs
Morgan Stanley (co-lead)
Credit Suisse
Lazard Capital
Cowen & Co.
Wedbush PacGrow

$200

 

Med BioGene Inc. (Canada; CDNX:MBI)2

12/28/09

N/A

N/A

N/A

Rodman & Renshaw LLC

$24

 

NuPathe Inc. (PATH)3

5/14/10

5S

$14-$16

14. 1

Leerink Swann
Lazard Capital (co-lead)
Needham & Co.

$75

 

Prometheus Laboratories Inc. (RXDX)

12/19/07

N/A

N/A

N/A

Goldman Sachs & Co.
Credit Suisse (co-lead)
SunTrust Robinson Humphrey
Cowen & Co.
WedBush PacGrow Life Sci.

$151.3

 

Trius Therapeutics Inc. (TSRX)4

11/6/09

10S

$5

23.6

Citibank
Piper Jaffray
Canaccord Genuity
JMP Securities

$50


Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; CDNX = Canadian Venture Exchange; General shelf registration statements are not included until action is taken on the filing; * Stock symbols for companies seeking to complete IPOs are proposed; @ This column reflects the shares outstanding following the offering, when disclosed; N/A = Not available, applicable or reported; The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing; 1 Human Stem Cell's IPO is filed for the Moscow Interbank Currency Exchange. 2 Med BioGene secured Rodman & Renshaw for an IPO in the U.S. 3 NuPathe's overallotment option: 750,000 shares. 4 Trius' overallotment option: 750,000 shares.